SEARCH

SEARCH BY CITATION

References

  • Assil IQ, Qi L, Arai M, Shomali M, Abou SA (2001). Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction. Biochemistry 40: 11871195.
  • Beyermann M, Rothemund S, Heinrich N, Fechner K, Furkert J, Dathe M et al. (2000). A role for a helical connector between two receptor binding sites of a long-chain peptide hormone. J Biol Chem 275: 57025709.
  • Christopoulos A, Kenakin T (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323374.
  • Dautzenberg FM, Hauger RL (2002). The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23: 7177.
  • Dautzenberg FM, Wille S, Braun S, Hauger RL (2002). GRK3 regulation during CRF- and urocortin-induced CRF1 receptor desensitization. Biochem Biophys Res Commun 298: 303308.
  • Grammatopoulos DK, Dai YL, Randeva HS, Levine MA, Karteris E, Easton AJ et al. (1999). A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Mol Endocrinol 13: 21892202.
  • Grammatopoulos DK, Randeva HS, Levine MA, Katsanou ES, Hilhouse EW (2000). Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1 alpha and R2 beta CRH receptor subtypes and stimulation of Gq-proteins. Mol Endocrinol 14: 20762091.
  • Hillhouse EW, Grammatopoulos DK (2006). The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: Implications for physiology and pathophysiology. Endocr Rev 27: 260286.
  • Hoare SR, Sullivan SK, Ling N, Crowe PD, Grigoriadis DE (2003). Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol Pharmacol 63: 751765.
  • Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD et al. (2004). Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G protein and nonpeptide antagonists. Biochemistry 43: 39964011.
  • Jensen AA, Spalding TA (2004). Allosteric modulation of G protein coupled receptors. Eur J Pharm Sci 21: 407420.
  • Kenakin T (2002). Efficacy at G protein-coupled receptors. Nat Rev Drug Discov 1: 103110.
  • Liaw CW, Grigoriadis DE, Lorang MT, de Souza EB, Maki RA (1997). Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 11: 20482053.
  • Nielsen SM, Nielsen LZ, Hjorth SA, Perrin MH, Vale WW (2000). Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras. Proc Natl Acad Sci USA 97: 1027710281.
  • Pradier L, Menager J, Le-Guern J, Bock M-D, Heuillet E, Fardin V et al. (1994). Septide: an agonist for the NK1 receptor acting at a site distinct from substance P. Mol Pharmacol 45: 287293.
  • Reinhart GJ, Xie Q, Liu XJ, Zhu YF, Fan J, Chen C et al. (2004). Species selectivity of nonpeptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus. J Biol Chem 279: 3411534122.
  • Soudijn W, Van-Wijngaarden I, Ijzerman AP (2002). Allosteric modulation of G protein-coupled receptors. Curr Opin Drug Discov Dev 5: 749755.
  • Strader CD, Fong TM, Tota MR, Underwood D, Dixon RA (1994). Structure and function of G protein-coupled receptors. Annu Rev Biochem 63: 101132.
  • Wietfeld D, Heinrich N, Furkert J, Fechner K, Beyermann M, Bienert M et al. (2004). Regulation of the coupling to different G proteins of rat corticotropin-releasing factor receptor type 1 in human embryonic kidney 293 cells. J Biol Chem 279: 3838638394.
  • Zhang G, Huang N, Li YW, Qi X, Marshall AP, Yan XX et al. (2003). Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/−)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors. J Pharmacol Exp Ther 305: 5769.